Cabaletta Bio Shares Rise on Autoimmune-Disease Trial Results
By Katherine Hamilton
Cabaletta Bio shares gained after the company shared positive clinical data about its trials for treatment of multiple autoimmune diseases.
The stock rose 13% to $2.79. Shares are up 23% this year.
The clinical data reinforces the potential of a single weight-based dose of Cabaletta's treatment rese-cel to deliver durable, drug-free clinical responses across multiple autoimmune diseases, Chief Medical Officer David Chang said Monday.
Rese-cel is an investigational cell therapy designed for the treatment of autoimmune diseases. It is administered as an infusion.
The data showed consistent responses through the primary endpoint of the registrational cohort of patients, Chang said. The Philadelphia-based company plans to initiate a registrational trial for treating the muscle-inflammation disease myositis, and anticipates the Food and Drug Administration will align on the designs for its lupus and systemic sclerosis trials.
Cabaletta said it is also accelerating its plans to initiate a no-preconditioning dose-escalation cohort for its systemic-sclerosis trial.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
October 27, 2025 13:03 ET (17:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States